<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00668876</url>
  </required_header>
  <id_info>
    <org_study_id>furukawa2008</org_study_id>
    <nct_id>NCT00668876</nct_id>
  </id_info>
  <brief_title>Effects of Immunonutrition in Patients Undergoing Pancreaticoduodenectomy</brief_title>
  <official_title>Effects of Immunonutrition on Surgical Site Infection and Th1/Th2/Th17 Differentiation in Patients Undergoing Pancreaticoduodenectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiba University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiba University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether immunonutrition is effective on surgical
      site infection and Th1/Th2/Th17 differentiation in patients undergoing
      pancreaticoduodenectomy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Perioperative immunonutrition is reported to improve the incidence of postoperative
      infectious complication in patients with gastrointestinal surgery. It has also been
      recognized that Th1/Th2 balance shifts toward Th2 by surgical stress. On the other hand, the
      change of Th17 status after surgery has not been established. Furthermore, The change of
      Th1/Th2 balance and Th17 status with immunonutrition on pancreaticoduodenectomy have not been
      reported yet.

      Objective of this study is to investigate the effects of perioperative immunonutrition on
      incidence of postoperative infectious complication, Th1/Th2 balance and Th17 status after
      pancreaticoduodenectomy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>surgical site infection after surgery</measure>
    <time_frame>30days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma IL-6, CRP, Th1/Th2 balance, Th17 status</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Pancreaticoduodenectomy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A: perioperative immunonutrition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group B: postoperative immunonutrition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group C: control</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral IMPACT</intervention_name>
    <description>oral supplementation for 5 days(1 L/d )before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA</description>
    <arm_group_label>1</arm_group_label>
    <other_name>oral IMPACT; Ajinomoto Pharma Co., Ltd, Tokyo, Japan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral IMPACT</intervention_name>
    <description>postoperative enteral infusion of the formula with arginine, omega-3 fatty acids, and RNA</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Parenteral nutrition</intervention_name>
    <description>Parenteral nutrition</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients underwent pancreaticoduodenectomy

        Exclusion Criteria:

          -  age younger than 18 years or older than 75 years

          -  preoperative chemotherapy or radiation

          -  ongoing infection

          -  diabetes mellitus

          -  gastrointestinal obstruction

          -  respiratory dysfunction

          -  cardiac dysfunction

          -  hepatic dysfunction

          -  renal failure

          -  history of recent immunosuppressive or immunological diseases

          -  preoperative evidence of widespread metastatic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daisuke Suzuki</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chiba University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chiba University</name>
      <address>
        <city>Chiba</city>
        <zip>260-8670</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2008</study_first_submitted>
  <study_first_submitted_qc>April 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2008</study_first_posted>
  <last_update_submitted>December 2, 2008</last_update_submitted>
  <last_update_submitted_qc>December 2, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2008</last_update_posted>
  <responsible_party>
    <name_title>Chiba University</name_title>
    <organization>Chiba University</organization>
  </responsible_party>
  <keyword>immunonutrition</keyword>
  <keyword>pancreaticoduodenectomy</keyword>
  <keyword>Th1</keyword>
  <keyword>Th2</keyword>
  <keyword>Th17</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

